StockWatch
·
Q2 FY-2027 RESULTS · PRIVISCL

Privi Q2 FY27: Consolidated PAT +30% YoY to ₹117.5 Cr as margins expand, beats Street

PAT +30.29% YoY · revenue +12.04% · margins expanding · beat vs street

Q2 FY27 resultsPRIVISCLPrivi Speciality Chemicals Ltd29 Oct 2026 · 3 min read
Revenue

₹760.45 Cr

+12.04% YoY

PAT (consolidated)

₹117.53 Cr

+30.29% YoY

Net margin

15.2%

+1.9pp YoY

EPS

₹29.96

Privi Speciality Chemicals' consolidated results for the quarter ended September 30, 2026 (Q2 FY27) comfortably cleared the bar set by our pre-result preview. Revenue from operations came in at ₹760.45 Cr, above the previewed ₹680-710 Cr range and up 12.0% YoY (₹678.71 Cr) and 14.1% QoQ (₹666.22 Cr). Consolidated PAT of ₹117.53 Cr was up 30.3% YoY and 41.9% QoQ, well clear of the ₹82-92 Cr the preview flagged as on-plan — a clean beat on both lines, consistent with Motilal Oswal's pre-result Buy thesis built on the medium-term execution case. No exceptional or one-off items are disclosed in either the standalone or consolidated statements this quarter, so the growth is on a like-for-like basis.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹760.45 Cr+14.1%+12%
Expenses₹614.62 Cr+8.2%+11%
PAT₹117.53 Cr+41.88%+30.29%
Net margin15.2%+3pp+1.9pp
EPS₹29.96+39%+24.6%

Margins did the heavy lifting behind the profit beat. Consolidated EBITDA margin (PBT adjusted for other income, finance cost and depreciation, over revenue from operations) worked out to ~26.3%, recovering sharply from Q1 FY27's ~22.9% and roughly matching the year-ago quarter's 26.8% — back near the >25% level management has guided it will sustain. Net profit margin (PAT over total income) expanded to ~15.2%, up from 13.3% a year ago and 12.2% last quarter. Standalone PAT of ₹119.3 Cr was broadly in line with the consolidated figure (~1.5% higher), so there's no material standalone-versus-consolidated divergence to flag.

₹
3,197.363,338.513,479.653,620.793,761.943,417.407-2708-1809-0910-0510-2810-29Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹3,417.4, down 5.3% over the past month of trading.

₹ Cr
043.8887.76131.6357.55Q1 FY26rev ₹559 Cr90.21Q2 FY26rev ₹679 Cr74.85Q3 FY26rev ₹605 Cr94.11Q4 FY26rev ₹722 Cr82.84Q1 FY27rev ₹666 Cr117.53Q2 FY27rev ₹760 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Scheme of Amalgamation cleared its shareholder vote on Oct 27, 2026 pursuant to the NCLT order

What management guided (1 FY-2027 call)
Reaffirmed ₹5,000 Cr revenue and ₹1,000+ Cr EBITDA target in 3-4 years with 20% CAGR. EBITDA margins expected to sustain around 25% driven by operational efficiencies and product mix. Phase-1 capacity (48K→54K MT) delayed to Sep 2026; Phase-2 to 66K MT by Sep 2027. ₹850-900 Cr capex over next 3 years.

— This quarter: met

On guidance, management's medium-term target of ₹5,000 Cr revenue and ₹1,000+ Cr EBITDA within 3-4 years (20% CAGR) is only partly on track: this quarter's 12.0% YoY revenue growth trails the 20% CAGR pace, even as the ~26.3% EBITDA margin print is already running ahead of the "around 25%" margin guidance from the last call — margin delivery is ahead of plan while topline growth needs to accelerate to hit the multi-year target. The company did not issue an accompanying press release or MD&A commentary with this filing, so there is no fresh management quote to weigh against the numbers; the only qualitative colour this quarter comes from the board's other actions disclosed alongside the results — a first interim dividend of ₹5/share (record date November 4, 2026) and the October 27, 2026 shareholder approval of the NCLT-directed Scheme of Amalgamation.

  • W1

    Revenue growth reacceleration toward the 20% CAGR guided pace (current YoY growth 12.0% trails it)

  • W2

    Phase-1 capacity move from 48K to 54K MT (targeted Sep 2026) — confirm ramp-up and its effect on the ~26.3% EBITDA margin in coming quarters

  • W3

    Scheme of Amalgamation progress toward NCLT sanction/effective date after the Oct 27, 2026 shareholder approval

Consolidated PAT ₹117.53 Cr is total net profit for the period (incl. NCI ₹0.51 Cr); owners-attributable PAT is ₹117.03 Cr, consistent with reported EPS ₹29.96. No exceptional items disclosed in either statement. Source is a clean text-based PDF (₹ Lakhs), columns unambiguous.

Informational and educational content only. Not investment advice.